Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERZ4 | ISIN: US2528281080 | Ticker-Symbol: 87E
Tradegate
31.03.25
15:39 Uhr
17,100 Euro
+0,600
+3,64 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DIANTHUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DIANTHUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
14,80015,00020:40
14,80015,00020:40

Aktuelle News zur DIANTHUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DIANTHUS THERAPEUTICS Aktie jetzt für 0€ handeln
12.03.Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Time to Sell?2
12.03.Stifel maintains Buy rating on Dianthus Therapeutics stock1
11.03.Dianthus Therapeutics GAAP EPS of -$0.81 beats by $0.04, revenue of $1.33M beats by $0.47M2
11.03.Dianthus Therapeutics, Inc. /DE/ - S-8, Securities to be offered to employees in employee benefit plans1
11.03.Dianthus Therapeutics, Inc. /DE/ - 10-K, Annual Report3
11.03.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results88Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy...
► Artikel lesen
05.03.Dianthus Therapeutics appoints John King as CCO2
05.03.Dianthus Therapeutics, Inc.: Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors4
05.03.Dianthus Therapeutics, Inc. /DE/ - 8-K, Current Report-
18.02.Dianthus serviced residences at Tropicana Gardens PJ receives GBI Silver certification1
20.12.24Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics1
20.12.24Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at TD Cowen1
12.12.24Dianthus Therapeutics, Inc. /DE/ - 8-K, Current Report-
11.11.24Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts3
08.11.24A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts2
08.11.24Dianthus Therapeutics GAAP EPS of -$0.74, revenue of $2.17M3
07.11.24Dianthus Therapeutics, Inc. /DE/ - 10-Q, Quarterly Report-
15.10.24Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting1
08.08.24Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results181Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June...
► Artikel lesen
12.06.24Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)175Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1